Global HR+/HER2- Breast Cancer Market 2016: What is the Overall Market Potential for First-in-class Product Ibrance? - Research and Markets

News provided by

Research and Markets

11 Aug, 2016, 04:10 ET

DUBLIN, August 11, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Breast Cancer: HR+/HER2-" report to their offering.

Ibrance's continued uptake and the approvals of several pipeline therapies will drive the growth of the HR+/HER2- breast cancer market.

This report addresses the following questions:

- Which branded therapies will have the largest impact on the HR+/HER2- breast cancer market?
- What is the overall market potential for first-in-class product Ibrance?
- How will competing CDK4/6 inhibitors ribociclib and abemaciclib fare following the earlier launch of Ibrance?
- How will PI3K inhibitors alpelisib, buparlisib, and taselisib be positioned in the market?
- When will generic and biosimilar therapies enter the market and what impact will they have on revenues?

Key Topics Covered:

FORECAST: HR+/HER2 BREAST CANCER

- Abemaciclib
- Afinitor (everolimus)
- Alpelisib
- Avastin (bevacizumab)
- Buparlisib
- Entinostat
- Faslodex (fulvestrant)
- Halaven (eribulin mesylate)
- Ibrance (palbociclib)
- Ixempra (ixabepilone)
- Lynparza (olaparib)
- Niraparib
- Ribociclib
- Talazoparib
- Taselisib
- Veliparib
- Primary Research Methodology

TREATMENT: HR+/HER2 BREAST CANCER

- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in HR+/HER
- Breast Cancer

EPIDEMIOLOGY: HER+/HER2 BREAST CANCER

- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: HR+/HER2 BREAST CANCER

- Product profile: Afinitor
- Product profile: Avastin
- Product profile: Faslodex
- Product profile: Halaven
- Product profile: Ibrance
- Product profile: Ixempra

PIPELINE: HR+/HER2 BREAST CANCER

- Product profile (late stage): Lynparza
- Product profile (late stage): abemaciclib
- Product profile (late stage): alpelisib
- Product profile (late stage): buparlisib
- Product profile (late stage): entinostat
- Product profile (late stage): niraparib
- Product profile (late stage): ribociclib
- Product profile (late stage): talazoparib
- Product profile (late stage): taselisib
- Product profile (late stage): veliparib

For more information visit http://www.researchandmarkets.com/research/2slmd4/breast_cancer

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Also from this source

Global Dermatology Drugs Market Set to Skyrocket, Anticipated Valuation of $50.47 Billion by 2032

Precision Medicine Takes Center Stage: Innovative Report Explores the Role of Companion Diagnostics in Transforming Healthcare

Explore

More news releases in similar topics

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.